Vitamin D3 for Life

Live Enlightened

Article

Tissue-specific expression and regulation: Study Summary

Previous related pageTissue-specific expression and regulation: Full Study SummaryNext related pageTissue-Specific Vitamin D Metabolism
Study at a glance

Why does a vitamin D-processing gene respond differently across tissues?

This study examined why a vitamin D-processing gene responds differently in the kidneys and other tissues. The gene, Cyp24a1, makes an enzyme that helps break down vitamin D compounds. Researchers removed two DNA control regions in mice and tested hormone responses. Human kidney tissue was examined separately to look for related control features.

What happened after the first DNA change?

Removing the region called DS1 greatly reduced the gene’s usual kidney activity and disrupted responses to parathyroid hormone and FGF23. Active vitamin D could still increase activity. The increase was about 740 times the starting value in altered mice, compared with 46 times in the comparison mice. The larger ratio came from a much lower starting point; it did not mean a greater final activity level.

Did changes to vitamin D controls also change blood minerals and bone density?

The gene involved in vitamin D activation also became less active. The pattern of vitamin D compounds changed, but active vitamin D in the blood, calcium, phosphate and bone density stayed broadly similar. Other controls appeared to make up for these changes. Removing the second region, DS2, reduced responses to active vitamin D outside the kidneys without stopping them. Several DNA regions could support the response.

Do these changes in mice show the same vitamin D controls in people?

The DNA sections were removed in mice, so their measured effects cannot be transferred directly to people. Human tissue showed related but more complex arrangements. Apparently normal mineral levels did not mean that the underlying controls were normal. The study also did not show that every tissue outside the kidneys uses the same control pattern.

Read the full article below ↓

Meyer and colleagues asked why Cyp24a1, the gene encoding a major vitamin D catabolic enzyme, responds to a complex endocrine programme in kidney but is regulated differently in non-renal tissues. Their experiments show that the answer lies partly in tissue-specific chromatin architecture: kidney uses a pCREB-rich downstream regulatory region for normal basal expression and PTH/FGF23 control, while calcitriol/VDR responsiveness is distributed across several regulatory elements and is more broadly shared across tissues.

What did the researchers study?

The study combined ChIP-seq, enhancer-associated histone mapping, CRISPR/Cas9 genomic deletions, hormonal challenge experiments, renal and non-renal RNA measurements, serum vitamin D metabolite profiling and human kidney chromatin analysis.

Two downstream regions were tested directly. C24-DS1 contained strong kidney-associated pCREB sites and was deleted across approximately 17.5 kb. C24-DS2 contained major VDR sites and was deleted across approximately 2.4 kb. These deletions allowed the researchers to move from “a factor binds here” to the stronger question of whether the region is actually required for gene regulation.

What happened when the kidney-selective DS1 region was deleted?

Basal renal Cyp24a1 expression fell markedly. The mutant kidney also lost normal regulation of Cyp24a1 by PTH and FGF23, establishing that the DS1 region is a major component of the kidney-specific endocrine response.

Cyp27b1 was secondarily suppressed, which is important because it shows that activation and catabolism are coupled. Disturbing Cyp24a1 regulation changes the endocrine environment experienced by the activating enzyme rather than producing an isolated gene-expression defect.

Despite the strong molecular effect, the mice had no striking gross phenotype under the studied conditions. Size, weight, bone mineral density, serum calcium and phosphate were broadly preserved, although PTH was modestly lower and FGF23 somewhat higher. This suggests substantial physiological compensation.

Why is the 46-fold versus 740-fold result important?

Calcitriol could still induce renal Cyp24a1 after DS1 deletion. Wild-type expression rose roughly 46-fold above baseline, while the mutant showed an approximately 740-fold increase.

The 740-fold value is easy to misread. The mutant started from an abnormally low baseline because DS1 deletion had collapsed basal Cyp24a1 expression. Its large fold change therefore does not mean that the mutant reached a vastly greater absolute expression level; the induced response was described as somewhat compromised. The result shows that VDR-dependent induction survives while the kidney-specific basal/PTH/FGF23 module is lost.

What did the metabolite measurements show?

The metabolic phenotype was selective rather than a simple rise in calcitriol. Serum 25(OH)D3 increased from about 14.8 to 51.0 ng/ml, while 24,25(OH)2D3 increased from about 7.8 to 26.5 ng/ml, leaving their ratio close to 2 in both groups.

The C23-associated pathway changed much more strongly. 25(OH)D3-26,23-lactone fell from about 3.1 to 1.1 ng/ml and the 25(OH)D3-to-lactone ratio rose from roughly 4.9 to 47.3. Circulating calcitriol itself was similar at about 24.6 versus 26.8 pg/ml. These values show how regulatory changes can redistribute vitamin D metabolites without producing a simple “more active hormone” pattern.

What did the DS2 deletion reveal?

Deleting the VDR-rich DS2 region reduced calcitriol responsiveness in non-renal target cells but did not abolish it, and renal induction also persisted. The most useful conclusion is redundancy: Cyp24a1 is regulated through several VDR-responsive elements rather than one universal enhancer.

That helps explain tissue differences. Kidney combines specialised pCREB-associated endocrine control with VDR feedback, whereas non-renal tissues can rely more heavily on distributed VDR-responsive elements and other local regulatory inputs.

What are the main limitations?

The causal enhancer deletions were performed in mice. Human kidney chromatin showed broadly related VDR, pCREB and enhancer-associated regions, but the human organisation was more overlapping and complex. The mouse deletion effect should therefore not be translated directly into a quantitative human prediction.

The study also does not show that every non-renal tissue behaves identically. “Non-renal” covers many cell types with different signalling environments. The central finding is tissue dependence, not a single alternative programme that applies everywhere outside kidney.

Why does this matter for vitamin D physiology?

The study shows that the same CYP24A1 enzyme can participate in different physiological jobs depending on how its gene is regulated. The broader Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) overview places this reciprocal enzyme control in context. In kidney, CYP24A1 is part of reciprocal endocrine control with CYP27B1. In non-renal tissues, local VDR-driven feedback can dominate. Gene presence therefore does not tell you, by itself, which hormones control the enzyme or whether the tissue contributes mainly to systemic or local vitamin D regulation.

Primary source and further reading

Meyer MB, Lee SM, Carlson AH, Benkusky NA, Kaufmann M, Jones G, Pike JW. A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues. Journal of Biological Chemistry. 2019;294(39):14467 to 14481. PMID 31439663; PMCID PMC6768633; DOI 10.1074/jbc.RA119.010173.

Read the full Meyer et al. paper. The Full Evidence Review develops the chromatin, deletion and metabolite evidence in greater depth.

Related reading

Original sources

Source

Read the full Meyer et al. paper

Read the full Meyer et al.

Publication details

Read the full Meyer et al. paper. The Full Evidence Review develops the chromatin, deletion and metabolite evidence in greater depth.

Read more →